Welcome!

Agile Computing Authors: Elizabeth White, Ed Featherston, Pat Romanski, Liz McMillan, Yeshim Deniz

News Feed Item

QIAGEN Adds to Pipeline of Personalized Healthcare Diagnostics Through Agreements for Promising New Biomarkers

HILDEN, Germany and GERMANTOWN, Maryland, January 7, 2013 /PRNewswire/ --


  • QIAGEN invests in new companion diagnostic being developed by Drug Response Dx that aims to predict efficacy of TNF-alpha inhibitors in rheumatoid arthritis patients
  • Rights to RET, ROS1 and DEPDC1 biomarkers gained from Insight Genetics offer promise as companion diagnostics in lung cancer
  • New tests from Inserm for mutations of HSP110 gene target diagnostic data on specific types of colorectal cancer, complementing other companion diagnostics

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced three separate agreements that add multiple biomarkers to QIAGEN's deep development pipeline of diagnostics for Personalized Healthcare applications to guide treatments with various medicines based on a patient's genomic information.

QIAGEN intends to develop new diagnostics to guide treatment decisions (including companion diagnostics paired with medicines) based on these biomarkers for use in therapeutic areas such as rheumatoid arthritis, lung cancer and colorectal cancer. Most of these assays will be designed to run on the QIAsymphony RGQ modular laboratory workflow automation system as well as QIAGEN's next-generation sequencing workflows currently in development. By guiding treatment decisions for specific therapies in individual patients, the use of these biomarkers as companion diagnostics can help improve patient outcomes and better utilize healthcare resources.

"These new agreements add further depth to our extensive development portfolio of biomarkers with potential to provide valuable diagnostic information as well as personalized guidance for treatment decisions. The opportunity to create a new, improved paradigm in the important and vast field of rheumatoid arthritis is very exciting, and the other agreements further deepen our pipeline in oncology," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "QIAGEN's global leadership in co-developing Personalized Healthcare solutions in partnership with pharmaceutical and biotechnology companies has become a key growth driver for our business. Our diagnostics are delivering molecular information to transform medical care for a wide range of diseases."

Rheumatoid arthritis

QIAGEN has made a strategic equity investment in Drug Response Dx GmbH with the option to obtain worldwide rights to biomarkers for evaluation of rheumatoid arthritis (RA) patients to guide treatment with TNF-alpha inhibitors, which are widely prescribed for treatment of RA.

Rheumatoid arthritis is a chronic inflammatory disease that affects 70 million patients worldwide. Therapy with TNF-alpha inhibitors is successful in approximately 60-70% of RA patients, but treatment failure does not become apparent for about six months. A companion diagnostic to predict which RA patients are likely to respond to TNF-alpha inhibitors would improve quality of life for patients through tailored and earlier use of the most effective drugs, while also decreasing costs due to failed treatments. This test would be highly complementary in the RA marketplace with QuantiFERON-TB Gold, QIAGEN's gold standard test for detection of latent tuberculosis (TB), since the prescribing information for many TNF-alpha inhibitors and other biological medicines requires testing for latent TB before use of the medicines.

Drug Response Dx, based in Hennigsdorf, Germany, is being financed at this stage by QIAGEN and High-Tech Gründerfonds GmbH, a German investor in early-stage companies and a co-founder of Drug Response Dx, which has developed proprietary RA biomarkers based on technology licensed from Max-Planck-Innovation.

Lung cancer  

QIAGEN has agreed to license exclusive worldwide rights from Insight Genetics Inc., a molecular diagnostics company in Nashville, Tennessee, for the RET, ROS1 and DEPDC1 biomarkers for use in non-small cell lung cancer (NSCLC), the most common form of lung cancer.

The agreement with Insight addresses a significant unmet need in the diagnosis and treatment of NSCLC. Collectively, RET, ROS1 and DEPDC1 mutations are estimated to be present in up to about one in ten of all NSCLC cases, but so far there are no regulatory-approved commercial tests to reliably and efficiently identify these biomarkers. Therapies targeting RET and ROS1 have shown good efficacy in clinical trials, so companion diagnostics have the potential to help identify patients who carry these mutations and could benefit from new targeted cancer therapies.

Previously, QIAGEN and Insight entered a licensing and co-development partnership for companion diagnostics focusing on the ALK gene, which several pharmaceutical companies are targeting for new anticancer treatments. The development of the EM4-ALK assay for use on the QIAsymphony automation system is progressing well. Mutations of ALK are implicated in NSCLC and other malignancies, and several compounds known as ALK inhibitors are in clinical trials; one ALK inhibitor already is on the market.

Colorectal cancer  

QIAGEN Marseille (QIAGEN's subsidiary previously known as Ipsogen) has licensed exclusive worldwide rights to a biomarker for mutations of the HSP110 gene, which allows for identification of specific types of colorectal cancer, from InsermTransfert, the technology transfer arm of the French National Institute of Health and Medical Research (Inserm) in Paris. QIAGEN intends to develop the biomarkers into a diagnostic test for routine use in the diagnostic work-up of colorectal cancer patients.

Diagnosing HSP110 mutations holds promise for enabling doctors to identify so-called microsatellite instability (MSI), which occurs in about 15% of all colorectal cancers. Patients with MSI have a more favorable outcome. On the other hand, about one-third of these patients with MSI have Lynch syndrome, an inherited form of colorectal cancer that is linked to a higher risk of developing a second cancer. The detection of this mutation is expected to help in assessing the MSI phenotype of colorectal cancer. The HSP110 biomarker will complement QIAGEN's therascreen tests that identify genetic mutations of the KRAS and BRAF genes in colorectal cancer patients.

Excellence in Personalized Healthcare

QIAGEN is a leading partner globally in developing and validating companion diagnostics to guide the selection of medicines in treating cancer and other diseases. In July 2012, QIAGEN received FDA approval for the therascreen® KRAS RGQ PCR Kit as a companion diagnostic in patients with metastatic colorectal cancer. The U.S. rollout of therascreen KRAS builds on a strong global leadership position including successes in Japan, where regulators approved the therascreen KRAS and EGFR kits in 2011, and in Europe, where QIAGEN offers 10 CE-marked assays for personalized healthcare applications. QIAGEN has more than 15 projects under way to co-develop and market companion diagnostics with leading pharmaceutical and biotechnology companies.

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2012, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Contacts:

Public Relations:
Dr. Thomas Theuringer
Director Public Relations
+49-2103-29-11826
+1-240-686-7425
Email: [email protected]

http://www.twitter.com/qiagen

http://www.qiagen.com/about/press

Investor Relations:
John Gilardi
VP Corporate Communications
+49-2103-29-11711
+1-240-686-2222

Peter Vozzo
Director, Global Investor Relations
+1-240-751-7400
Email: [email protected]

http://www.qiagen.com/about/investorrelation


SOURCE Qiagen N.V.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, discussed the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Two weeks ago (November 3-5), I attended the Cloud Expo Silicon Valley as a speaker, where I presented on the security and privacy due diligence requirements for cloud solutions. Cloud security is a topical issue for every CIO, CISO, and technology buyer. Decision-makers are always looking for insights on how to mitigate the security risks of implementing and using cloud solutions. Based on the presentation topics covered at the conference, as well as the general discussions heard between sessio...
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
Announcing Poland #DigitalTransformation Pavilion
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
CloudEXPO | DXWorldEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
The best way to leverage your CloudEXPO | DXWorldEXPO presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering CloudEXPO | DXWorldEXPO will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at CloudEXPO. Product announcements during our show provide your company with the most reach through our targeted audienc...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
Everything run by electricity will eventually be connected to the Internet. Get ahead of the Internet of Things revolution. In his session at @ThingsExpo, Akvelon expert and IoT industry leader Sergey Grebnov provided an educational dive into the world of managing your home, workplace and all the devices they contain with the power of machine-based AI and intelligent Bot services for a completely streamlined experience.
DXWorldEXPO | CloudEXPO are the world's most influential, independent events where Cloud Computing was coined and where technology buyers and vendors meet to experience and discuss the big picture of Digital Transformation and all of the strategies, tactics, and tools they need to realize their goals. Sponsors of DXWorldEXPO | CloudEXPO benefit from unmatched branding, profile building and lead generation opportunities.
22nd International Cloud Expo, taking place June 5-7, 2018, at the Javits Center in New York City, NY, and co-located with the 1st DXWorld Expo will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud ...
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
"MobiDev is a software development company and we do complex, custom software development for everybody from entrepreneurs to large enterprises," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
JETRO showcased Japan Digital Transformation Pavilion at SYS-CON's 21st International Cloud Expo® at the Santa Clara Convention Center in Santa Clara, CA. The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, added the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor analytic...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...